Fortress Biotech Reports Strong Q3 Growth and Pipeline Progress
MIAMI, FL — November 14, 2025 — Fortress Biotech announced its third-quarter 2025 financial results, highlighting sustained revenue growth,...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
MIAMI, FL — November 14, 2025 — Fortress Biotech announced its third-quarter 2025 financial results, highlighting sustained revenue growth,...
SEATTLE, WA – November 13, 2025 — Pelthos Therapeutics released its third-quarter fiscal 2025 financial results, highlighting strong R&D...
